News

On-demand PrEP protects high-risk men against HIV


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

References

“The science has spoken. There can now be no excuse for inaction,” they said.

This study was funded in part by the French National Agency of Research on AIDS and Viral Hepatitis (ANRS). Dr. Molina reports grant support from the ANRS during the conduct of the study, grant support and personal fees from Merck and Gilead, and personal fees from Bristol-Myers Squibb, ViiV, and Janssen outside the submitted work. Dr. Fauci and Dr. Marston reported having no disclosures. Detailed disclosure statements for all authors are available with the full text of the article at NEJM.com.

sworcester@frontlinemedcom.com

Pages

Recommended Reading

Study: Disproportionately high HIV infection rate for Hispanics
MDedge Infectious Disease
HIV testing low among patients admitted for pneumonia
MDedge Infectious Disease
HHS awards $2.2 billion for HIV/AIDS care in FY 2015
MDedge Infectious Disease
Efavirenz-based therapy an option for HIV-infected children
MDedge Infectious Disease
FDA approves new single-tablet HIV treatment
MDedge Infectious Disease
Study: Marketplace silver plans offer poor access to HIV drugs
MDedge Infectious Disease
PrEP effective in preventing HIV acquisition in MSM and transgender women
MDedge Infectious Disease
Study questions efficacy of NRTIs in HIV salvage therapy
MDedge Infectious Disease
Global HIV treatment goals face resource challenges
MDedge Infectious Disease
Are you PrEPping your high HIV-risk patients?
MDedge Infectious Disease